Prevalence of small for gestational age (SGA) and short stature in children born SGA who qualify for growth hormone treatment at 3 years of age: Population-based study

Kaori Fujita, Miwako Nagasaka, Sota Iwatani, Tsubasa Koda, Daisuke Kurokawa, Keiji Yamana, Kosuke Nishida, Mariko Ikeda, Eiko Uchino, Chika Shirai, Kazumoto Iijima, Ichiro Morioka

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: To treat children born small for gestational age (SGA) with severe short stature, treatment with growth hormone (GH) has been approved in the USA, Europe, and Japan, but no population-based studies have reported their prevalence. The aims of this study were to investigate the prevalence of SGA and short stature in children born SGA who qualify for GH treatment at 3 years of age in a Japanese population. Methods: A population-based study was conducted in Kobe, Japan with 27 228 infants who were born between 2006 and 2008 and followed until 3 years of age. Prevalence of birthweight (BW) or birth length (BL) ≤ −2.0 standard deviation scores (SDS) for gestational age (GA; definition of SGA) was calculated. Short children born SGA who qualify for GH treatment at 3 years of age were estimated using the following criteria: BW and BL below the 10th percentile for GA, BW or BL ≤ −2.0 SDS for GA, and 2.5 SDS below the mean height for age. Results: The prevalence of SGA was 3.5%. The estimated prevalence of short stature in children born SGA who met the criteria for GH treatment was 0.06%. The prevalence in infants born <34 weeks (0.39%) was significantly higher than that in infants born 34–41 weeks GA (0.05%, P = 0.02). Conclusions: The prevalence of SGA and short stature in children born SGA who qualify for GH treatment is approximately 1 of 30 infants and 1 of 1800 children, respectively. The risk is increased when children are born <34 weeks GA.

Original languageEnglish
Pages (from-to)372-376
Number of pages5
JournalPediatrics International
Volume58
Issue number5
DOIs
Publication statusPublished - 01-05-2016

Fingerprint

Growth Hormone
Gestational Age
Population
Therapeutics
Parturition
Japan

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Fujita, Kaori ; Nagasaka, Miwako ; Iwatani, Sota ; Koda, Tsubasa ; Kurokawa, Daisuke ; Yamana, Keiji ; Nishida, Kosuke ; Ikeda, Mariko ; Uchino, Eiko ; Shirai, Chika ; Iijima, Kazumoto ; Morioka, Ichiro. / Prevalence of small for gestational age (SGA) and short stature in children born SGA who qualify for growth hormone treatment at 3 years of age : Population-based study. In: Pediatrics International. 2016 ; Vol. 58, No. 5. pp. 372-376.
@article{c4a8cf63ec0840a1bba547ce6eea8db1,
title = "Prevalence of small for gestational age (SGA) and short stature in children born SGA who qualify for growth hormone treatment at 3 years of age: Population-based study",
abstract = "Background: To treat children born small for gestational age (SGA) with severe short stature, treatment with growth hormone (GH) has been approved in the USA, Europe, and Japan, but no population-based studies have reported their prevalence. The aims of this study were to investigate the prevalence of SGA and short stature in children born SGA who qualify for GH treatment at 3 years of age in a Japanese population. Methods: A population-based study was conducted in Kobe, Japan with 27 228 infants who were born between 2006 and 2008 and followed until 3 years of age. Prevalence of birthweight (BW) or birth length (BL) ≤ −2.0 standard deviation scores (SDS) for gestational age (GA; definition of SGA) was calculated. Short children born SGA who qualify for GH treatment at 3 years of age were estimated using the following criteria: BW and BL below the 10th percentile for GA, BW or BL ≤ −2.0 SDS for GA, and 2.5 SDS below the mean height for age. Results: The prevalence of SGA was 3.5{\%}. The estimated prevalence of short stature in children born SGA who met the criteria for GH treatment was 0.06{\%}. The prevalence in infants born <34 weeks (0.39{\%}) was significantly higher than that in infants born 34–41 weeks GA (0.05{\%}, P = 0.02). Conclusions: The prevalence of SGA and short stature in children born SGA who qualify for GH treatment is approximately 1 of 30 infants and 1 of 1800 children, respectively. The risk is increased when children are born <34 weeks GA.",
author = "Kaori Fujita and Miwako Nagasaka and Sota Iwatani and Tsubasa Koda and Daisuke Kurokawa and Keiji Yamana and Kosuke Nishida and Mariko Ikeda and Eiko Uchino and Chika Shirai and Kazumoto Iijima and Ichiro Morioka",
year = "2016",
month = "5",
day = "1",
doi = "10.1111/ped.12859",
language = "English",
volume = "58",
pages = "372--376",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "5",

}

Fujita, K, Nagasaka, M, Iwatani, S, Koda, T, Kurokawa, D, Yamana, K, Nishida, K, Ikeda, M, Uchino, E, Shirai, C, Iijima, K & Morioka, I 2016, 'Prevalence of small for gestational age (SGA) and short stature in children born SGA who qualify for growth hormone treatment at 3 years of age: Population-based study', Pediatrics International, vol. 58, no. 5, pp. 372-376. https://doi.org/10.1111/ped.12859

Prevalence of small for gestational age (SGA) and short stature in children born SGA who qualify for growth hormone treatment at 3 years of age : Population-based study. / Fujita, Kaori; Nagasaka, Miwako; Iwatani, Sota; Koda, Tsubasa; Kurokawa, Daisuke; Yamana, Keiji; Nishida, Kosuke; Ikeda, Mariko; Uchino, Eiko; Shirai, Chika; Iijima, Kazumoto; Morioka, Ichiro.

In: Pediatrics International, Vol. 58, No. 5, 01.05.2016, p. 372-376.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevalence of small for gestational age (SGA) and short stature in children born SGA who qualify for growth hormone treatment at 3 years of age

T2 - Population-based study

AU - Fujita, Kaori

AU - Nagasaka, Miwako

AU - Iwatani, Sota

AU - Koda, Tsubasa

AU - Kurokawa, Daisuke

AU - Yamana, Keiji

AU - Nishida, Kosuke

AU - Ikeda, Mariko

AU - Uchino, Eiko

AU - Shirai, Chika

AU - Iijima, Kazumoto

AU - Morioka, Ichiro

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background: To treat children born small for gestational age (SGA) with severe short stature, treatment with growth hormone (GH) has been approved in the USA, Europe, and Japan, but no population-based studies have reported their prevalence. The aims of this study were to investigate the prevalence of SGA and short stature in children born SGA who qualify for GH treatment at 3 years of age in a Japanese population. Methods: A population-based study was conducted in Kobe, Japan with 27 228 infants who were born between 2006 and 2008 and followed until 3 years of age. Prevalence of birthweight (BW) or birth length (BL) ≤ −2.0 standard deviation scores (SDS) for gestational age (GA; definition of SGA) was calculated. Short children born SGA who qualify for GH treatment at 3 years of age were estimated using the following criteria: BW and BL below the 10th percentile for GA, BW or BL ≤ −2.0 SDS for GA, and 2.5 SDS below the mean height for age. Results: The prevalence of SGA was 3.5%. The estimated prevalence of short stature in children born SGA who met the criteria for GH treatment was 0.06%. The prevalence in infants born <34 weeks (0.39%) was significantly higher than that in infants born 34–41 weeks GA (0.05%, P = 0.02). Conclusions: The prevalence of SGA and short stature in children born SGA who qualify for GH treatment is approximately 1 of 30 infants and 1 of 1800 children, respectively. The risk is increased when children are born <34 weeks GA.

AB - Background: To treat children born small for gestational age (SGA) with severe short stature, treatment with growth hormone (GH) has been approved in the USA, Europe, and Japan, but no population-based studies have reported their prevalence. The aims of this study were to investigate the prevalence of SGA and short stature in children born SGA who qualify for GH treatment at 3 years of age in a Japanese population. Methods: A population-based study was conducted in Kobe, Japan with 27 228 infants who were born between 2006 and 2008 and followed until 3 years of age. Prevalence of birthweight (BW) or birth length (BL) ≤ −2.0 standard deviation scores (SDS) for gestational age (GA; definition of SGA) was calculated. Short children born SGA who qualify for GH treatment at 3 years of age were estimated using the following criteria: BW and BL below the 10th percentile for GA, BW or BL ≤ −2.0 SDS for GA, and 2.5 SDS below the mean height for age. Results: The prevalence of SGA was 3.5%. The estimated prevalence of short stature in children born SGA who met the criteria for GH treatment was 0.06%. The prevalence in infants born <34 weeks (0.39%) was significantly higher than that in infants born 34–41 weeks GA (0.05%, P = 0.02). Conclusions: The prevalence of SGA and short stature in children born SGA who qualify for GH treatment is approximately 1 of 30 infants and 1 of 1800 children, respectively. The risk is increased when children are born <34 weeks GA.

UR - http://www.scopus.com/inward/record.url?scp=84975691240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975691240&partnerID=8YFLogxK

U2 - 10.1111/ped.12859

DO - 10.1111/ped.12859

M3 - Article

C2 - 26617415

AN - SCOPUS:84975691240

VL - 58

SP - 372

EP - 376

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 5

ER -